PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24934473-2 2015 Genistein modified PES/PVP membranes reveal significant reduction of the reactive oxygen species and also considerable suppression of interleukin-1beta and tumor necrosis factor-alpha levels in whole blood, but to a lesser extent ininterleukin-6. Genistein 0-9 interleukin 1 beta Homo sapiens 134-183 25447760-3 2014 150 kGy gamma-irradiated genistein did not exert cytotoxicity in macrophages, and inhibited inducible nitric oxide synthase-mediated nitric oxide production and pro-inflammatory cytokines level, such as tumor necrosis factor-alpha, interleukin-6 and interleukin-1beta, in lipopolysaccharide (LPS)-induced macrophages. Genistein 25-34 interleukin 1 beta Homo sapiens 250-267 24669186-8 2014 RESULTS: Genistein decreased the secretion of IL-1beta, IL-6, and IL-8 from TNF-alpha-stimulated MH7A cells in a dose-dependent manner. Genistein 9-18 interleukin 1 beta Homo sapiens 46-54 25319548-10 2014 Genistein significantly decreased IL-6 and IL-1beta mRNA levels, as well as IL-6 production in PMA/A23187-induced mast cells activation. Genistein 0-9 interleukin 1 beta Homo sapiens 43-51 21792602-7 2012 IL-1beta or TNF-alpha increased expression of MMP-9 and MMP-2 in rheumatoid synoviocytes; EGF stimulated expression of MMP-9 but not of MMP-2; genistein suppressed production of MMP-9 more than MMP-2 induced by IL-1beta or TNF-alpha; rMMP-9, rMMP-2, or their inhibitors had no effect on the (3)H-TdR incorporation of synovial cells. Genistein 143-152 interleukin 1 beta Homo sapiens 0-8 22521737-5 2012 In contrast, genistein, an estrogen receptor ligand, postpones the activation of MAPKs induced by IL-1beta. Genistein 13-22 interleukin 1 beta Homo sapiens 98-106 21792602-6 2012 Genistein had an inhibitory role on cell number and (3)H-TdR incorporation of RA-FLS stimulated with IL-1beta, TNF-alpha and EGF; genistein arrested the cell cycle at G(1) restriction point; genistein decreased colony numbers under anchorage-independent condition stimulated by EGF in serum condition. Genistein 0-9 interleukin 1 beta Homo sapiens 101-109 21792602-7 2012 IL-1beta or TNF-alpha increased expression of MMP-9 and MMP-2 in rheumatoid synoviocytes; EGF stimulated expression of MMP-9 but not of MMP-2; genistein suppressed production of MMP-9 more than MMP-2 induced by IL-1beta or TNF-alpha; rMMP-9, rMMP-2, or their inhibitors had no effect on the (3)H-TdR incorporation of synovial cells. Genistein 143-152 interleukin 1 beta Homo sapiens 211-219 21792602-11 2012 Genistein inhibited IL-1beta, TNF-alpha or EGF-induced proliferation and MMP-9 expression in fibroblast-like synoviocytes of rheumatoid arthritis; the proliferation of RA-FLS was mediated by Erk1/2 but not JNK activation, while JNK activation was involved in the signal transduction pathway leading to MMP-9 expression in rheumatoid synoviocytes. Genistein 0-9 interleukin 1 beta Homo sapiens 20-28 18377686-8 2008 Ellagic acid, genistein and epigallocatechin gallate reduced (4- to 8-fold) IL-1beta-induced IL-8 secretion, while resveratrol promoted (1.7-fold) the secretion. Genistein 14-23 interleukin 1 beta Homo sapiens 76-84 21657246-10 2011 Of particular importance is that the genistein-modified blend membranes (PA:PVP/G) showed greater suppression of the concentrations of all three cytokines (TNF-alpha, IL-1beta, and IL-6) in comparison with those of the PA/G membranes, signifying the role of PVP in the enhanced anti-inflammatory properties of these genistein-modified membranes. Genistein 37-46 interleukin 1 beta Homo sapiens 167-175 12714616-17 2003 Genistein (50 microM) and dexamethasone (1 microM) also partially blocked (by 26% and 28%, respectively) the effect of IL-1beta. Genistein 0-9 interleukin 1 beta Homo sapiens 119-127 18202522-8 2007 The IL-1beta-stimulated uPA mRNA expression and PA activities in the cell lysate and medium were reduced by the tyrosine kinase inhibitors herbimycin A and genistein, and by the NFkappaB inhibitor pyrolidinedithiocarbamate, and were augmented by the tyrosine phosphatase inhibitor sodium orthovanadate. Genistein 156-165 interleukin 1 beta Homo sapiens 4-12 11093788-2 2000 Tyrosine kinase inhibitors (genistein or tyrphostin 23) or phosphatidylcholine-specific phospholipase C inhibitor (D609) attenuated IL-1beta-induced ICAM-1 expression. Genistein 28-37 interleukin 1 beta Homo sapiens 132-140 11996950-9 2002 Use of specific tyrosine kinase inhibitor herbimycin A, genistein, or PP2 (Src family kinase inhibitor) indicated that tyrosine kinases are required for IL-1beta-stimulated and beta-VLDL-enhanced nitrite accumulation, while specific inhibition of ERK1/2 or p38-MAP kinase had no effects. Genistein 56-65 interleukin 1 beta Homo sapiens 153-161 11076808-5 2000 Neutralizing antibodies to epidermal growth factor (EGF) and transforming growth factor-alpha or inhibition of the EGF receptor by tyrphostin AG-1478 or genistein inhibited IL-1beta-induced alveolar epithelial repair, indicating that IL-1beta enhances in vitro alveolar epithelial repair by an EGF- or transforming growth factor-alpha-dependent mechanism. Genistein 153-162 interleukin 1 beta Homo sapiens 173-181 11775830-4 2000 Genistein, the specific PTK inhibitor, was used to evaluate the inhibitory role in activation of MAPKs by IL-1 beta. Genistein 0-9 interleukin 1 beta Homo sapiens 106-115 10068525-10 1999 RESULTS: TLCK, genistein, and LLnL each inhibited IL-1beta-induced C3 production in a dose-dependent fashion. Genistein 15-24 interleukin 1 beta Homo sapiens 50-58 10942208-9 2000 This increase of DNA-protein complex formation induced by IL-1beta was blocked by herbimycin A and another tyrosine kinase inhibitor, genistein. Genistein 134-143 interleukin 1 beta Homo sapiens 58-66 10688620-4 2000 Genistein also blocks the effect of IL-1beta, indicating involvement of tyrosine phosphorylation in the process. Genistein 0-9 interleukin 1 beta Homo sapiens 36-44 10198191-5 1999 IL-1 beta-induced accumulations of VEGF mRNA in cardiac myocytes were abolished by the tyrosine kinase inhibitor genistein, whereas inhibition of protein kinase C (PKC) by staurosporin, calphostin C and phorbol ester-induced PKC depletion, and intracellular Ca2+ chelators did not affect the induction of VEGF mRNA by IL-1 beta. Genistein 113-122 interleukin 1 beta Homo sapiens 0-9 10198191-5 1999 IL-1 beta-induced accumulations of VEGF mRNA in cardiac myocytes were abolished by the tyrosine kinase inhibitor genistein, whereas inhibition of protein kinase C (PKC) by staurosporin, calphostin C and phorbol ester-induced PKC depletion, and intracellular Ca2+ chelators did not affect the induction of VEGF mRNA by IL-1 beta. Genistein 113-122 interleukin 1 beta Homo sapiens 318-327 10617676-3 2000 The tyrosine kinase inhibitors (genistein and tyrphostin AG126) and phosphatidylcholine-phospholipase C inhibitor (D-609) prevented IL-1beta-induced prostaglandin E(2) (PGE(2)) release and COX-2 expression, whereas U-73122 (a phosphatidylinositol-phospholipase C inhibitor) and propranolol (a phosphatidate phosphohydrolase inhibitor) had no effect. Genistein 32-41 interleukin 1 beta Homo sapiens 132-140 8764139-8 1996 We further show that the tyrosine kinase inhibitors genistein and herbimycin A prevent IL-1 beta plus IFN-gamma-induced expression of COX-2 and iNOS and the production of PGE2 and nitric oxide by human islets. Genistein 52-61 interleukin 1 beta Homo sapiens 87-96 9551901-8 1998 In dendritic cells generated from mononuclear progenitors, the protein tyrosine kinase inhibitor genistein was able to block tyrosine phosphorylation as well as production of IL-1beta mRNA transcripts. Genistein 97-106 interleukin 1 beta Homo sapiens 175-183 8928785-2 1996 Induction of iNOS transcription?by a combination of the cytokines interferon-gamma and IL-1 beta was inhibited by genistein, pyrrolidine dithiocarbamate, or dexamethasone and unaffected by pretreatment with ethylene glycol-bis(beta-aminoethyl ether)-N, N,N",N"-tetraacetic acid, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), or the isoflavone daidzein. Genistein 114-123 interleukin 1 beta Homo sapiens 87-96 8967514-7 1996 Pretreatment of cells with genistein (0.37 microM), a specific tyrosine kinase inhibitor, attenuated the proliferative effect of IL-1 beta and PDGF-BB. Genistein 27-36 interleukin 1 beta Homo sapiens 129-138 8967514-10 1996 In contrast, genistein pretreatment (0.37 microM) prevented formation of inositol 1,4,5-trisphosphate (IP3), as induced by IL-1 beta and/or PDGF-BB. Genistein 13-22 interleukin 1 beta Homo sapiens 123-132 7541794-5 1995 The tyrosine kinase inhibitors genistein and herbimycin A block both integrin-mediated tyrosine phosphorylation and increases in IL-1 beta message levels, indicating a causal relationship between the two events. Genistein 31-40 interleukin 1 beta Homo sapiens 129-138 8587246-8 1995 Inhibition study using protein kinase inhibitors revealed that MCP-1 mRNA expression induced by IL-1 beta and TNF-alpha was suppressed by the tyrosine kinase inhibitor genistein, not by the protein kinase C inhibitors staurosporine or H-7, or the protein kinase A inhibitor H-89, suggesting an important role of tyrosine kinase in the cytokine-induced MCP-1 gene expression. Genistein 168-177 interleukin 1 beta Homo sapiens 96-105 11854837-4 1995 Genistein, an inhibitor of tyrosine phosphorylation completely inhibited the ability of IL-1beta to induce the COX II message. Genistein 0-9 interleukin 1 beta Homo sapiens 88-96 7861699-10 1994 The structurally distinct protein tyrosine kinase (PTK) inhibitors genistein, herbimycin A, and tyrphostin each caused a dose-dependent inhibition of the effects of IL-1 on mesangial MCP-1 activity. Genistein 67-76 interleukin 1 beta Homo sapiens 165-169 7875467-8 1995 However, induction of IL-8 by IL-1 beta or TNF-alpha was reduced by the PTK inhibitors herbimycin (by 79% or 89%, respectively) and genistein (by > 95%). Genistein 132-141 interleukin 1 beta Homo sapiens 30-39 30901677-7 2019 Moreover, Genistein treatment down-regulated production of caspase-1 and IL-1beta and increased intracellular cAMP level, which were similar to the treatment for INT-777, a semi-synthetic TGR5 agonist, in phorbol myristate acetate (PMA)-differentiated monocytic THP-1 cells and U937 cells. Genistein 10-19 interleukin 1 beta Homo sapiens 73-81 8089188-9 1994 When adhering monocytes are treated with the tyrosine kinase inhibitors genistein or herbimycin, both phosphorylation of pp76 and induction of IL-1 beta message are blocked in a dose-dependent fashion. Genistein 72-81 interleukin 1 beta Homo sapiens 143-152 8089188-10 1994 Similarly, treatment with genistein or herbimycin can block tyrosine phosphorylation of pp76 and IL-1 beta message induction mediated by ligation of beta 1 integrin with antibodies. Genistein 26-35 interleukin 1 beta Homo sapiens 97-106 8340234-9 1993 Two tyrosine kinase inhibitors, genistein and dihydroxycinnamate, both inhibited SEB-induced IL-1 beta mRNA in monocytes. Genistein 32-41 interleukin 1 beta Homo sapiens 93-102 8454038-2 1993 Genistein, a specific tyrosine kinase inhibitor, inhibited PMA induced IL-1 beta protein and mRNA levels in THP-1 cells. Genistein 0-9 interleukin 1 beta Homo sapiens 71-80 1639516-3 1992 In contrast, the secretion of IL-1 beta was blocked by a cyclic AMP- and cyclic GMP-dependent kinase inhibitor (HA1004) as well as by H7 and genistein. Genistein 141-150 interleukin 1 beta Homo sapiens 30-39 31137797-2 2019 This compound has anti-inflammatory, anti-oxidative, and anti-cancer effects; however, the mechanism underlying the effects of genistein on IL-1beta-stimulated human osteoarthritis (OA) chondrocytes remains unknown. Genistein 127-136 interleukin 1 beta Homo sapiens 140-148 31137797-3 2019 Our objectives in this study were to explore the anti-inflammatory effects of genistein on IL-1beta-stimulated human OA chondrocytes and to investigate the potential mechanisms which underlie them. Genistein 78-87 interleukin 1 beta Homo sapiens 91-99 31137797-4 2019 Our results from an in-vitro model of osteoarthritis indicate that genistein inhibits the IL-1beta-induced expression of the catabolic factors nitric oxide synthase 2 (NOS2), cyclooxygenase 2 (COX-2), and matrix metalloproteinases (MMPs). Genistein 67-76 interleukin 1 beta Homo sapiens 90-98